The Medical Letter on Drugs and Therapeutics
Dapagliflozin/Saxagliptin (Qtern) for Type 2 Diabetes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Qtern (AstraZeneca), a fixed-dose combination of the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin (Farxiga) and the dipeptidyl peptidase-4 (DPP-4) inhibitor saxagliptin (Onglyza), for oral treatment of adults with type 2 diabetes. Dapagliflozin and saxagliptin have each been available for years alone and in combination with extended-release metformin (Xigduo XR; Kombiglyze XR).1 Three SGLT2/DPP-4 inhibitor combinations are now available in the US (see Table 2).

CLINICAL STUDIES — In a trial in 320 patients with a glycated hemoglobin (A1C) of 7-10.5% who were stabilized on open-label treatment with metformin and saxagliptin 5 mg/day for 8-16 weeks and then randomized to addition of dapagliflozin 10 mg/day or placebo for 24 weeks, the mean change from baseline in A1C, the ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Dapagliflozin Saxagliptin (Qtern) for Type 2 Diabetes
Article code: 1543d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian